Samsrita Labs Limited
BBSE:SAMSRITA12.96
INR
+1.17
(+9.92%)
ISIN
INE579N01018
Return %
Stock
S&P 500
1Y
-38.69
14.20
3Y
-22.72
81.12
5Y
-55.77
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Konagalla Nagavenkata V. Narendra Kumar
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 6-3-354 Hyderabad TS India 500082
- IPO Date
- Aug 11, 2015
- Website
- drhlsl.com
- Similar Companies
- Business
- Samsrita Labs Limited Samsrita Labs Ltd (SAMSRITA.BO) operates as a biopharmaceutical and healthcare company focused on advanced research, diagnostics, and therapeutic development in India. Incorporated in 1996 and headquartered in Hyderabad, Telangana, the company offers stem cell research and therapy targeting organs including liver, pancreas, neural, cardiac, vascular, renal, and orthopedic for end-stage diseases; new drug discovery in therapeutic areas such as Wilson’s disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular disease, cystinosis, and Huntington’s disease with 11 international patents; molecular diagnostics encompassing DNA, RNA, and chromosomal-based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, pre-natal and pre-implantation genetic diagnostics using technologies like qPCR, MLPA, NGS, karyotyping, and FISH; medical devices including extra-corporeal liver support devices, bioengineered implantable nerve conduits, implantable nanochips for insulin delivery, and nanotechnology-based devices for circulating tumor cell removal and sepsis management; contract research organization services in synthetic chemistry, medicinal chemistry, drug development, API process research, natural products, and analytics; biomarker discovery via miRNA panels; and hospital services through stem cell-based multi-specialty facilities. The company provides molecular prognosis and diagnostics in cytogenetics, pharmacogenomics, pathology, radiology, hematology, biochemistry, and microbiology to patients, consultants, hospitals, and institutions primarily in India. Formerly known as Dr. Habeebullah Life Sciences Limited and prior to that PC Products India Limited, it changed its name to Samsrita Labs Limited in October 2022; recent developments include a July 2025 preferential allotment of equity shares via share swap making Qrops Advisory Services Private Limited an associate with a 28.62% stake, expectations of INR 38.4 million funding announced in April 2025, amendments to memorandum of association for increased authorized capital and new objects clauses approved in May 2025, and substantial acquisition disclosures under SEBI regulations in November 2025.